ライフサイエンスコーパス: vascular dementia

1 ing cerebrovascular disease, and 44 cases of vascular dementia).

2 ar dementia, and non-Alzheimer's disease non-vascular dementia).

3 ar dementia, and non-Alzheimer's disease non-vascular dementia).

4 nt dementia (n = 532 AD and n = 154 mixed or vascular dementia).

5 urysm, aortic dissection, and more recently, vascular dementia.

6 ascular dementia) and sub-cortical ischaemic vascular dementia.

7 RNA to be markedly elevated in AD but not in vascular dementia.

8 also significantly elevated in AD but not in vascular dementia.

9 s blood brain barrier (BBB) permeability and vascular dementia.

10 A(A)) agonist, mitigates the AD syndrome and vascular dementia.

11 to support widespread use of these drugs in vascular dementia.

12 proval in most of the world for treatment of vascular dementia.

13 oke, and be a solid substrate for developing vascular dementia.

14 se inhibitors and memantine in patients with vascular dementia.

15 f cholinesterase inhibitors and memantine in vascular dementia.

16 gnificance in patients with mild to moderate vascular dementia.

17 cutive impairment as a diagnostic marker for vascular dementia.

18 ight serve as a useful diagnostic marker for vascular dementia.

19 milder stages of Alzheimer's disease or for vascular dementia.

20 ern was observed for Alzheimer's disease and vascular dementia.

21 d risk of dementia, Alzheimer's disease, and vascular dementia.

22 e burden of heart failure, and 6) preventing vascular dementia.

23 hard to classify, and one was diagnosed with vascular dementia.

24 size of neurons in CA1 in AD versus ischemic vascular dementia.

25 ps of alcohol use with Alzheimer disease and vascular dementia.

26 lts were similar for Alzheimer's disease and vascular dementia.

27 to increased risk of Alzheimer's disease and vascular dementia.

28 attributed primarily to Alzheimer disease or vascular dementia.

29 ia of the Alzheimer type (DAT), but not with vascular dementia.

30 airment, mimicking the human presentation of vascular dementia.

31 ith a low risk of Alzheimer disease and less vascular dementia.

32 and is the most common pathology underlying vascular dementia.

33 factors for apparently 'sporadic' stroke and vascular dementia.

34 l small vessel disease, the leading cause of vascular dementia.

35 ses of Alzheimer's dementia and 418 cases of vascular dementia.

36 , a hallmark of Alzheimer's disease (AD) and vascular dementia.

37 iated with lower risk of ischemic stroke and vascular dementia.

38 associated with incident ischemic stroke and vascular dementia.

39 ase, heart failure, stroke, hypertension and vascular dementia.

40 including multiple WM strokes that result in vascular dementia.

41 ise was associated with an increased risk of vascular dementia.

42 L, the leading inherited cause of stroke and vascular dementia.

43 cardial infarction are at increased risk for vascular dementia.

44 portant pathogenic factor in the etiology of vascular dementia.

45 may provide one of the mechanisms underlying vascular dementia.

46 s dementia and 0.84 (95% CI: 0.77, 0.91) for vascular dementia.

47 ic risk factors and ignores outcomes such as vascular dementia.

48 ies, sepsis, or even Alzheimer's disease and vascular dementia.

49 an increasing prevalence of both stroke and vascular dementia.

50 burden of heart failure, and (6) preventing vascular dementia.

51 esis and treatment of vascular aging, AD and vascular dementia.

52 possible avenue for restoring healthy CBF in vascular dementia.

53 ged brain might hold therapeutic promise for vascular dementia.

54 scular flow, such as Alzheimer's disease and vascular dementia.

55 itiate neuropathological events that lead to vascular dementia.

56 s, including the brain, where it can lead to vascular dementia.

57 ith Lewy bodies, frontotemporal dementia, or vascular dementia.

58 ying stroke onset or tolerance as well as in vascular dementia.

59 hippocampus and corpus callosum in rats with vascular dementia.

60 some human stroke patients that suffer from vascular dementia.

61 ery occlusion (BCCAO) was used as a model of vascular dementia.

62 tral nervous system injury in a rat model of vascular dementia.

63 g speed and more than quadrupled the risk of vascular dementia.

64 role of inflammatory cells in the genesis of vascular dementia.

65 which was similar for Alzheimer disease and vascular dementia.

66 .5%) had Alzheimer disease and 95 (8.1%) had vascular dementia.

67 sease dementia, frontotemporal dementia, and vascular dementia.

68 d in Alzheimer's disease and even more so in vascular dementia.

69 isease, there are no licensed treatments for vascular dementia.

70 e but only slightly and not significantly in vascular dementia.

71 y represent a novel therapeutic strategy for vascular dementia.

72 beta1-42 in Parkinson's disease dementia and vascular dementia.

73 zheimer's disease and vascular dementia, and vascular dementia.

74 erebral perfusion in Alzheimer's disease and vascular dementia.

75 rmal regulation of white matter perfusion in vascular dementia.

76 es in subjects with post-stroke dementia and vascular dementia.

77 ementia), with most cases being diagnosed as vascular dementia.

78 tive dysfunction in post-stroke dementia and vascular dementia.

79 successful against the progressive nature of vascular dementia.

80 d sequelae ranging from cognitive sparing to vascular dementia.

81 tly in patients with Alzheimer's disease and vascular dementia.

82 a leading cause of cognitive impairment and vascular dementia.

83 over 2 years in both Alzheimer's disease and vascular dementia.

84 troke survivors met the current criteria for vascular dementia.

85 y contribute to early cognitive decline and (vascular) dementia.

86 entia (KDMAge HR=1.19, 95% CI=1.11 to 1.26), vascular dementia (1.41, 1.25 to 1.60) and ischaemic str

87 1 [5]), 30 were patients diagnosed as having vascular dementia (37% female, mean [SD], 76 [9]; Mini-M

88 entia (HR, 2.0; 95% CI, 1.2-3.4), especially vascular dementia (4.3; 1.1-17.0), but not Alzheimer dis

89 oradic Alzheimer's disease, 81 patients with vascular dementia, 61 stroke patients without dementia,

90 samples from 82 patients with iNPH, 75 with vascular dementia, 70 with Parkinson's disease, 34 with

91 ssigned to one cluster and the patients with vascular dementia (91%), frontotemporal dementia (94%),

92 Vascular dementia accounts for approximately 15-20% of a

93 Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the

94 Compared to vascular dementia, AD-S individuals exhibited greater im

95 02, 95% CI 0.96-1.07; P = .58), and incident vascular dementia (adjusted HR 1.13, 95% CI 0.97-1.32; P

96 % confidence interval (CI) = 1.03-1.26]) and vascular dementia (adjusted HR = 1.32 [95% CI = 1.10-1.5

97 confidence interval: 1.12, 1.16), while for vascular dementia age-adjusted rates were higher for men

98 wever, MI was associated with higher risk of vascular dementia (aHR, 1.35; 95% CI, 1.28-1.43), which

99 disease (aHR, 1.60; 95% CI, 1.26-2.02), and vascular dementia (aHR, 1.38; 95% CI, 1.04-1.83).

100 The efficacy of memantine in vascular dementia also requires further investigation.

101 fectiveness of memantine in the treatment of vascular dementia, although it has not been approved for

102 schemic stroke, peripheral arterial disease, vascular dementia, Alzheimer disease, all-cause mortalit

103 Incident cases of total dementia, vascular dementia, Alzheimer disease-dementia in Alzheim

104 t dementia including Alzheimer's disease and vascular dementia, analyzing data from participants aged

105 r risk ratio of 0.69 (95% CI, 0.54-0.90) for vascular dementia and 0.91 (95% CI, 0.77-1.10) for Alzhe

106 n-Alzheimer's dementia (47 of which involved vascular dementia and 8 of which involved other types of

107 post-mortem tissue from Alzheimer's disease, vascular dementia and age-matched control brains.

108 ; the heterozygous live normally but develop vascular dementia and Alzheimer's disease (AD) in later

109 olinergic properties (AC AHT) on the risk of vascular dementia and Alzheimer's disease by emulating a

110 ential role for anti-inflammatory therapy in vascular dementia and Alzheimer's disease, and perhaps e

111 This is true for vascular dementia and Alzheimer's disease.

112 icated in neurodegenerative diseases such as vascular dementia and Alzheimer's disease.

113 tHcy) is a strong modifiable risk factor for vascular dementia and Alzheimer's disease.

114 n midlife atherosclerosis and development of vascular dementia and cerebral small vessel disease but

115 bral amyloid angiopathy (CAA) is a prevalent vascular dementia and common comorbidity of Alzheimer's

116 rug therapy, and the combination of keywords vascular dementia and drug therapy.

117 longer duration of treatment with AC AHT on vascular dementia and highlight the value of the target

118 t Kir2.1 as a possible therapeutic target in vascular dementia and indicate that concurrent mineraloc

119 y implicated in Alzheimer's disease (AD) and vascular dementia and its pathology remains unknown.

120 ntegrity and have been recently discussed in vascular dementia and neuroinflammatory disorders.

121 Frequency of stroke, vascular dementia and other clinical features of CADASIL

122 ls of two serotonin receptors in subtypes of vascular dementia and relate any changes to cognition.

123 athology and treatment choice for stroke and vascular dementia and speculates that considering a pati

124 r the apolipoprotein E polymorphism, and the vascular dementia and stroke groups were typed at the HL

125 various neuropathologic disorders including vascular dementia and stroke.

126 milar for Alzheimer disease, mixed dementia, vascular dementia and unspecified dementia.

127 lateral prefrontal cortex of post-stroke and vascular dementia and, of mixed and Alzheimer's disease

128 e artery territory infarction (multi-infarct vascular dementia) and sub-cortical ischaemic vascular d

129 a diagnosis of Alzheimer's disease, 8664 of vascular dementia, and 2192 of Parkinson's disease relat

130 eveloped Alzheimer disease, 64 men developed vascular dementia, and 250 men developed all-cause demen

131 was 9% (2.8% for Alzheimer disease, 1.6% for vascular dementia, and 4.5% for other dementias).

132 (65%) had Alzheimer's disease, 62 (19%) had vascular dementia, and 53 (16%) had another DSM-IV demen

133 to have neuroprotective effects on ischemic, vascular dementia, and amyloid-beta (Abeta)-infused anim

134 ortex of brain tissue from patients with AD, vascular dementia, and controls.

135 ith Lewy bodies, Parkinson disease dementia, vascular dementia, and dementia due to traumatic brain i

136 urden, a group less likely to be affected by vascular dementia, and in participants with ICAD causing

137 T allele significantly increases the risk of vascular dementia, and increases the risk of Alzheimer's

138 isk of developing all-cause, Alzheimer's, or vascular dementia, and investigated whether differences

139 ific dementia subtypes (Alzheimer's disease, vascular dementia, and non-Alzheimer's disease non-vascu

140 ia (all-cause dementia, Alzheimer's disease, vascular dementia, and non-Alzheimer's disease non-vascu

141 n encompassing diseases such as Alzheimer's, vascular dementia, and Parkinson's.

142 with increased risk of dementia, especially vascular dementia, and reduced total brain volumes.

143 mer's disease, mixed Alzheimer's disease and vascular dementia, and vascular dementia.

144 ations between AVAI and atrial fibrillation, vascular dementia, aortic aneurysm, and aortic dissectio

145 lar diseases, including atrial fibrillation, vascular dementia, aortic aneurysms, and aortic dissecti

146 Prevalence of vascular dementia appears to be slightly lower than in J

147 Intracerebral hemorrhagic stroke and vascular dementia are age- and hypertension-associated m

148 Stroke and vascular dementia are leading causes of morbidity and mo

149 al substrates associated with post-stroke or vascular dementia are poorly understood, particularly th

150 Death and thromboembolic outcomes, including vascular dementia, are substantially increased in patien

151 arcts and leukoencephalopathy (CADASIL) is a vascular dementia arising from abnormal arteriolar vascu

152 tterns were found with Alzheimer disease and vascular dementia as outcomes.

153 HR] = 4.59, 95% CI, 3.48-6.06), particularly vascular dementia (aSHR = 2.51, 95% CI, 1.01-6.25) and o

154 rains of patients with CADASIL, a hereditary vascular dementia associated with NOTCH3 missense mutati

155 Higher risk of AD and vascular dementia associated with residency close to hig

156 imer's disease, dementia with Lewy bodies or vascular dementia at presentation.

157 al dementia (AUC=82.76-100% across cohorts), vascular dementia (AUC=92.13%), progressive supranuclear

158 ., Alzheimer's disease, Parkinson's disease, vascular dementia, chronic traumatic encephalopathy), P7

159 oreactivity was increased in post-stroke and vascular dementia compared with post-stroke patients wit

160 memory abilities and morphology in rats with vascular dementia compared with rats with untreated vasc

161 Trials were of 6-month duration with similar vascular dementia criteria and outcome measures.

162 excess numbers of AD deaths among women and vascular dementia deaths among men remained, providing s

163 appeared largely attributable to underlying vascular dementia diagnoses (subhazard ratio, 1.16 [1.11

164 es were incident all-cause, Alzheimer's, and vascular dementia diagnoses obtained from self-report an

165 -1.29), AD (HR, 0.94; 95% CI, 0.55-1.63), or vascular dementia diagnosis (HR, 1.06; 95% CI, 0.65-1.70

166 All-cause dementia, AD, and vascular dementia diagnosis, as well as log-transformed

167 patients have reported that individuals with vascular dementia do better on memory tests and worse on

168 yle risk for CAD ~70% more likely to develop vascular dementia during follow-up compared with those i

169 51 (95% CI 1.49-4.21) for the development of vascular dementia for individuals with a CT or TT genoty

170 evelopment of dementia (eg, senile dementia, vascular dementia, frontotemporal dementia, and Alzheime

171 In the vascular dementia, frontotemporal dementia, dementia wit

172 tency in the normal distribution between the vascular dementia group and the control rats.

173 e distribution of TNF-alpha genotypes in the vascular dementia group differed significantly from that

174 prevalence rates of Alzheimer's disease and vascular dementia have differed.

175 es of abnormal gait, unsteady gait predicted vascular dementia (hazard ratio, 2.61), as did frontal g

176 , abnormal gait predicted the development of vascular dementia (hazard ratio, 3.46 [95 percent confid

177 ases, including stroke, Alzheimer's disease, vascular dementia, heart, and peripheral vascular diseas

178 .17, 95% CI 1.04-1.32; P = 0.010), driven by vascular dementia (HR 1.68, 95% CI 1.33-2.12; P < 0.001)

179 = 1.11 [1.03-1.19], p = 0.0044) and mixed or vascular dementia (HR = 1.21 [1.04-1.41], p = 0.0163).

180 e (HR = 1.393, 95% CI [1.290,1.504]; k = 5), vascular dementia (HR = 1.735, 95% CI [1.483,2.029]; k =

181 betes was more prominent in individuals with vascular dementia (HR = 1.94, 95% CI = 1.84-2.04).

182 disease (HR, 0.80 [95% CI, 0.63-1.02]), and vascular dementia (HR, 0.38 [95% CI, 0.18-0.80]) and an

183 nes were elevated in Alzheimer's disease and vascular dementia: IL-15 and IL-17A were maximally eleva

184 ubjects (Alzheimer's disease in 61 subjects, vascular dementia in 30, mixed dementia in 25, and other

185 nges alter the immune response to stroke and vascular dementia in animal and human studies.

186 d further has translational potential to map vascular dementia in diseased or injured human brains wi

187 dementias, including Alzheimer's disease and vascular dementia in elderly people.

188 e NOTCH3 gene trigger adult-onset stroke and vascular dementia in patients with CADASIL (cerebral aut

189 ubtypes (Alzheimer disease [AD] and mixed or vascular dementia) in older community-dwelling persons.

190 vascular function in Alzheimer's disease and vascular dementia, in superior temporal cortex (Brodmann

191 ) compared with control subjects, but not in vascular dementia, in which endothelin 1 tended to be el

192 and dementia (probable Alzheimer disease and vascular dementia, including possible Alzheimer disease

193 ness associated with Alzheimer's disease and vascular dementia, independently of the level of insolub

194 ith Alzheimer disease or other dementia like vascular dementia, indicative that these antibodies hold

195 ases according to this schema will subdivide vascular dementias into their underlying, potentially tr

196 racts were associated with increased risk of vascular dementia (inverse variance-weighted odds ratio

197 Vascular dementia is caused by different cerebrovascular

198 ) seen in patients with hypertension-induced vascular dementia is increasingly viewed as a therapeuti

199 Vascular dementia is now recognized as the second most c

200 Vascular dementia is one of the most common causes of de

201 essel disease leading to ischemic stroke and vascular dementia is the neurodegenerative syndrome cere

202 Next to Alzheimer disease, vascular dementia is the second most common form of deme

203 Vascular dementia is the second most common form of deme

204 Vascular dementia is the second most common type of deme

205 ans affected and acquired phenotypes such as vascular dementia, is still being defined.

206 f dementia such as Alzheimer's disease (AD), Vascular dementia, Lewy Body Dementia (LBD) and Frontote

207 with dementia (all types), AD dementia, and vascular dementia listed on the death certificate.

208 In Parkinson's disease dementia and vascular dementia low cerebrospinal fluid amyloid-beta1-

209 Vascular dementia may respond, at least to some extent,

210 ct vascular dementia, sub-cortical ischaemic vascular dementia, mixed Alzheimer's disease/vascular de

211 Dementia diagnoses (Alzheimer disease, vascular dementia, mixed dementia, dementia with Lewy bo

212 lassically used escape latency measures in a vascular dementia model and demonstrated a higher consis

213 ognitive disorders, including the hereditary vascular dementias, multi-infarct dementia, post-stroke

214 tem cohorts of Alzheimer's disease (n = 49), vascular dementia (n = 17) and control brains (n = 33) f

215 Alzheimer disease (n = 154) and vascular dementia (n = 36) were the 2 most frequent diag

216 ts with dementia (Alzheimer's disease, N=84; vascular dementia, N=60).

217 icipants included individuals with dementia (vascular dementia, nonvascular dementia, or Alzheimer di

218 ation in the brain of diabetic patients with vascular dementia or Alzheimer disease (AD), nondiabetic

219 cortex of patients with either multi-infarct vascular dementia or SND, compared to age-matched contro

220 vascular dementia, mixed Alzheimer's disease/vascular dementia or stroke no dementia (SND).

221 ased risk of stroke (OR: 2.33, p=0.0004) and vascular dementia (OR: 5.00, p=0.007), and increased whi

222 ses, Tenth Revision, codes for dementia (AD, vascular dementia, or unspecified dementia).

223 r dementia compared with rats with untreated vascular dementia (P < .05).

224 nificantly less in AD compared with ischemic vascular dementia (p < 0.02), but there was no significa

225 tive disorders, such as Alzheimer's disease, vascular dementia, Parkinson's disease, and Huntington's

226 from Alzheimer's disease patients (n = 75), vascular dementia patients (n = 22) and age-matched cont

227 onal decline in both Alzheimer's disease and vascular dementia patients over a 2-year period.

228 were exacerbated in Alzheimer's disease and vascular dementia patients, and also in non-dementia con

229 novel therapies for stroke and multi-infarct vascular dementia patients.

230 ) Alzheimer's disease patients, and 27 (45%) vascular dementia patients.

231 monoxide, CO: OR=1.587; higher incidence of vascular dementia per 1 mug/m(3) increase of nitrogen ox

232 ease (primary or contributing), and 4.2% for vascular dementia (primary or contributing).

233 The Alzheimer disease/vascular dementia ratio was 1.5 for cases attributed pri

234 NOTCH3 carriers had increased vascular dementia risk (OR, 5.42; 95% CI, 3.11-8.74), HT

235 re consistently observed in AD than ischemic vascular dementia, severity of loss shows the expected c

236 sporadic form of Alzheimer disease (AD) and vascular dementia share many risk factors, and their pat

237 The current narrow definitions of vascular dementia should be broadened to recognise the i

238 , and are associated with conditions such as vascular dementia, small vessel disease, cerebral amyloi

239 between the neurochemistry of multi-infarct vascular dementia/SND and sub-cortical ischaemic vascula

240 associated with lower CSF Abeta42 in AD and vascular dementia (standardized beta = -0.09, P = .003;

241 42 in control participants and patients with vascular dementia (standardized beta = -0.18, P = .002;

242 acunes was associated with higher Abeta42 in vascular dementia (standardized beta = 0.17, P = .07) an

243 rtices of patients with either multi-infarct vascular dementia, sub-cortical ischaemic vascular demen

244 s examining the neurochemistry of individual vascular dementia subtypes.

245 ular dementia/SND and sub-cortical ischaemic vascular dementia, suggesting that pharmacological manip

246 loid PET analysis, especially in subcortical vascular dementia (SVaD) patients.

247 Despite being a common cause of stroke and vascular dementia, the underlying pathogenesis is poorly

248 MI was associated with higher risk of vascular dementia throughout follow-up, and this associa

249 xpression in post-mortem brain tissue in AD, vascular dementia (VaD) and controls.

250 ls were measured in 20 AD, 20 control and 15 Vascular dementia (VaD) brains by real-time PCR (RT-PCR)

251 The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, an

252 While Alzheimer disease (AD) and vascular dementia (VaD) may be accelerated by hyperchole

253 ailable for 347 Alzheimer's disease (AD), 76 vascular dementia (VaD), and 811 control participants wi

254 d ratios (HRs) for Alzheimer's disease (AD), vascular dementia (VaD), and all-cause dementia in perso

255 cidence of dementia, Alzheimer disease (AD), vascular dementia (VaD), and CIND by age.

256 r categorised into Alzheimer's disease (AD), vascular dementia (VaD), and dementia caused by other di

257 he coexistence of Alzheimer disease (AD) and vascular dementia (VaD), is likely to increase as the po

258 ts major subtypes Alzheimer disease (AD) and vascular dementia (VaD), is not well known.

259 Vascular dementia (VaD), the second-leading cause of dem

260 onally considered as a separate disease from vascular dementia (VAD).

261 decreased risk of Alzheimer disease (AD) and vascular dementia (VaD).

262 pairment (CI), Alzheimer's disease (AD), and vascular dementia (VaD).

263 ic cerebral hypoperfusion is associated with vascular dementia (VaD).

264 gnoses of Alzheimer disease (AD), and 35% of vascular dementia (VaD).

265 model of chronic cerebral hypoperfusion and vascular dementia (VaD).

266 ivo biomarkers for Alzheimer's disease (AD), vascular dementia (VD) and Lewy body dementia (LBD) usin

267 of 2,511 Alzheimer's dementia (AD) and 1,308 Vascular Dementia (VD) cases.

268 ause dementia, Alzheimer's disease (AD), and vascular dementia (VD) incidence.

269 with late onset Alzheimer's disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a

270 mentia comprising Alzheimer disease (AD) and vascular dementia (VD) was identified by electronic link

271 ementia (FTD), Lewy body dementia (LBD), and vascular dementia (VD) were identified by ICD-10 diagnos

272 er's disease (AD), Parkinson's disease (PD), vascular dementia (VD), senile dementia (SD), mild cogni

273 th Alzheimer disease (AD) and 13 (2.6%) with vascular dementia (VD).

274 -cause dementia, Alzheimer disease (AD), and vascular dementia (VD).

275 Alzheimer's disease (AD; 1.8 [1.1-2.9]), and vascular dementia (VsD; 2.3 [1.1-5.0]).

276 participants (198 [39%] vs 77 [33%]), while vascular dementia was more common among Black participan

277 the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of th

278 Prevalence levels for Alzheimer disease and vascular dementia were also estimated.

279 rates of dementia, Alzheimer's disease, and vascular dementia were examined in the Japanese American

280 ADRD, AD, and vascular dementia were identified from electronic medica

281 Diagnoses of Alzheimer disease and vascular dementia were secondary outcome measures.

282 Carotid plaques were associated with vascular dementia when assessed as a 3-graded score (adj

283 with white matter hyperintensity burden and vascular dementia, whereas some Alzheimer's dementia ass

284 e patients with cerebral ischemic stroke and vascular dementia, which significantly increase the risk

285 eeded to identify subgroups of patients with vascular dementia who might benefit.

286 n has been implicated in the pathogenesis of vascular dementia, yet little is known about the cellula